These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 28411455)

  • 1. Identification of 3-substituted-6-(1-(1H-[1,2,3]triazolo[4,5-b]pyrazin-1-yl)ethyl)quinoline derivatives as highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitors via metabolite profiling-based structural optimization.
    Zhao F; Zhang LD; Hao Y; Chen N; Bai R; Wang YJ; Zhang CC; Li GS; Hao LJ; Shi C; Zhang J; Mao Y; Fan Y; Xia GX; Yu JX; Liu YJ
    Eur J Med Chem; 2017 Jul; 134():147-158. PubMed ID: 28411455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of a novel class of exquisitely selective mesenchymal-epithelial transition factor (c-MET) protein kinase inhibitors and identification of the clinical candidate 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (PF-04217903) for the treatment of cancer.
    Cui JJ; McTigue M; Nambu M; Tran-Dubé M; Pairish M; Shen H; Jia L; Cheng H; Hoffman J; Le P; Jalaie M; Goetz GH; Ryan K; Grodsky N; Deng YL; Parker M; Timofeevski S; Murray BW; Yamazaki S; Aguirre S; Li Q; Zou H; Christensen J
    J Med Chem; 2012 Sep; 55(18):8091-109. PubMed ID: 22924734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery and optimization of a series of imidazo[4,5-b]pyrazine derivatives as highly potent and exquisitely selective inhibitors of the mesenchymal-epithelial transition factor (c-Met) protein kinase.
    Zhao F; Zhang J; Zhang L; Hao Y; Shi C; Xia G; Yu J; Liu Y
    Bioorg Med Chem; 2016 Sep; 24(18):4281-4290. PubMed ID: 27448775
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of (S)-1-(1-(Imidazo[1,2-a]pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-[1,2,3]triazolo[4,5-b]pyrazine (volitinib) as a highly potent and selective mesenchymal-epithelial transition factor (c-Met) inhibitor in clinical development for treatment of cancer.
    Jia H; Dai G; Weng J; Zhang Z; Wang Q; Zhou F; Jiao L; Cui Y; Ren Y; Fan S; Zhou J; Qing W; Gu Y; Wang J; Sai Y; Su W
    J Med Chem; 2014 Sep; 57(18):7577-89. PubMed ID: 25148209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of 6-(difluoro(6-(4-fluorophenyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-3-yl)methyl)quinoline as a highly potent and selective c-Met inhibitor.
    Zhan Z; Peng X; Liu Q; Chen F; Ji Y; Yao S; Xi Y; Lin Y; Chen T; Xu Y; Ai J; Geng M; Duan W
    Eur J Med Chem; 2016 Jun; 116():239-251. PubMed ID: 27061987
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lessons from (S)-6-(1-(6-(1-methyl-1H-pyrazol-4-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl)ethyl)quinoline (PF-04254644), an inhibitor of receptor tyrosine kinase c-Met with high protein kinase selectivity but broad phosphodiesterase family inhibition leading to myocardial degeneration in rats.
    Cui JJ; Shen H; Tran-Dubé M; Nambu M; McTigue M; Grodsky N; Ryan K; Yamazaki S; Aguirre S; Parker M; Li Q; Zou H; Christensen J
    J Med Chem; 2013 Sep; 56(17):6651-65. PubMed ID: 23944843
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors.
    Peterson EA; Teffera Y; Albrecht BK; Bauer D; Bellon SF; Boezio A; Boezio C; Broome MA; Choquette D; Copeland KW; Dussault I; Lewis R; Lin MH; Lohman J; Liu J; Potashman M; Rex K; Shimanovich R; Whittington DA; Vaida KR; Harmange JC
    J Med Chem; 2015 Mar; 58(5):2417-30. PubMed ID: 25699405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
    Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
    Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery andw biological evaluation of novel 6,7-disubstituted-4-(2-fluorophenoxy)quinoline derivatives possessing 1,2,3-triazole-4-carboxamide moiety as c-Met kinase inhibitors.
    Zhou S; Liao H; Liu M; Feng G; Fu B; Li R; Cheng M; Zhao Y; Gong P
    Bioorg Med Chem; 2014 Nov; 22(22):6438-52. PubMed ID: 25438768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development and biochemical characterization of EGFR/c-Met dual inhibitors].
    Szokol B; Gyulavári P; Baska F; Ibolya K; Greff Z; Szántai KC; Zoltán O; Peták I; Axel U; Vantus T; Kéri G; Orfi L
    Acta Pharm Hung; 2013; 83(4):121-33. PubMed ID: 24575658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery of a novel 6,7-disubstituted-4-(2-fluorophenoxy)quinolines bearing 1,2,3-triazole-4-carboxamide moiety as potent c-Met kinase inhibitors.
    Liu M; Hou Y; Yin W; Zhou S; Qian P; Guo Z; Xu L; Zhao Y
    Eur J Med Chem; 2016 Aug; 119():96-108. PubMed ID: 27155466
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and c-Met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent.
    Wang Y; Ai J; Wang Y; Chen Y; Wang L; Liu G; Geng M; Zhang A
    J Med Chem; 2011 Apr; 54(7):2127-42. PubMed ID: 21405128
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
    Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
    Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of novel 4-(2-fluorophenoxy)quinoline derivatives as selective c-Met inhibitors.
    Wang X; Jiang N; Zhao S; Xi S; Wang J; Jing T; Zhang W; Guo M; Gong P; Zhai X
    Bioorg Med Chem; 2017 Feb; 25(3):886-896. PubMed ID: 28011202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Discovery of novel 4-(2-fluorophenoxy)quinoline derivatives bearing 4-oxo-1,4-dihydrocinnoline-3-carboxamide moiety as c-Met kinase inhibitors.
    Li S; Zhao Y; Wang K; Gao Y; Han J; Cui B; Gong P
    Bioorg Med Chem; 2013 Jun; 21(11):2843-55. PubMed ID: 23628470
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolism of c-Met Kinase Inhibitors Containing Quinoline by Aldehyde Oxidase, Electron Donating, and Steric Hindrance Effect.
    Zhang JW; Xiao W; Gao ZT; Yu ZT; Zhang JYJ
    Drug Metab Dispos; 2018 Dec; 46(12):1847-1855. PubMed ID: 30209037
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
    Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
    Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based discovery of novel 4-(2-fluorophenoxy)quinoline derivatives as c-Met inhibitors using isocyanide-involved multicomponent reactions.
    Nan X; Li HJ; Fang SB; Li QY; Wu YC
    Eur J Med Chem; 2020 May; 193():112241. PubMed ID: 32200199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer.
    Morgillo F; Amendola G; Della Corte CM; Giacomelli C; Botta L; Di Maro S; Messere A; Ciaramella V; Taliani S; Marinelli L; Trincavelli ML; Martini C; Novellino E; Ciardiello F; Cosconati S
    J Med Chem; 2017 Sep; 60(17):7447-7458. PubMed ID: 28787156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
    Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
    Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.